Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.

Abstract

Ketamine, a racemic mixture of (S)-ketamine and (R)-ketamine enantiomers, has been used as an anesthetic, analgesic and more recently, as an antidepressant. However, ketamine has known abuse liability (the tendency of a drug to be used in non-medical situations due to its psychoactive effects), which raises concerns for its therapeutic use. (S)-ketamine was recently approved by the United States' FDA for treatment-resistant depression. Recent studies showed that (R)-ketamine has greater efficacy than (S)-ketamine in preclinical models of depression, but its clinical antidepressant efficacy has not been established. The behavioral effects of racemic ketamine have been studied extensively in preclinical models predictive of abuse liability in humans (self-administration and conditioned place preference [CPP]). In contrast, the behavioral effects of each enantiomer in these models are unknown. We show here that in the intravenous drug self-administration model, the gold standard procedure to assess potential abuse liability of drugs in humans, rats self-administered (S)-ketamine but not (R)-ketamine. Subanesthetic, antidepressant-like doses of (S)-ketamine, but not of (R)-ketamine, induced locomotor activity (in an opioid receptor-dependent manner), induced psychomotor sensitization, induced CPP in mice, and selectively increased metabolic activity and dopamine tone in medial prefrontal cortex (mPFC) of rats. Pharmacological screening across thousands of human proteins and at biological targets known to interact with ketamine yielded divergent binding and functional enantiomer profiles, including selective mu and kappa opioid receptor activation by (S)-ketamine in mPFC. Our results demonstrate divergence in the pharmacological, functional, and behavioral effects of ketamine enantiomers, and suggest that racemic ketamine's abuse liability in humans is primarily due to the pharmacological effects of its (S)-enantiomer.

• Authors: Jordi Bonaventura, Sherry Lam, Meghan Carlton, Matthew A Boehm, Juan L Gomez, Oscar Solís, Marta Sánchez-Soto, Patrick J Morris, Ida Fredriksson, Craig J Thomas, David R Sibley, Yavin Shaham, Carlos A Zarate Jr, Michael Michaelides
• Journal: Molecular psychiatry (Mol Psychiatry) Vol. 26 Issue 11 Pg. 6704-6722 (11 2021) ISSN: 1476-5578 [Electronic] England
• PMID: 33859356 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)
• Copyright: © 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Chemical References

• Antidepressive Agents
• Ketamine

Topics

• Animals
• Antidepressive Agents (therapeutic use)
• Depression (metabolism)
• Depressive Disorder, Treatment-Resistant (drug therapy)
• Ketamine (therapeutic use)
• Mice
• Rats
• Stereoisomerism